The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-term follow-up of psilocybin-facilitated smoking cessation
Open accessAbstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As previously noted, mindfulness practices facilitate behavioral change by enabling individuals to identify triggers and habitual responses, whereas psychedelic therapy can amplify this awareness, resulting in even deeper behavioral transformations [33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Classic psychedelics, such as synthetic LSD and psilocybin, which is found in certain mushrooms, have shown promise as aids in psychotherapy e.g., for mood disorders and substance dependence [1, 5, 33].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is emerging evidence from early phase trials of nicotine dependence (14)”
From Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use (2024) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Psilocybin-assisted psychotherapy (PAT) also appears to be safe and potentially efficacious for substance use disorders, based on early trials for nicotine and alcohol use disorders [14,15], with little evidence of harmful use in the community [16].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Psilocybin occasioned mystical experiences are defined by acute feelings of unity, sacredness, a noetic quality, positive mood, transcendence of space/time, and ineffability (6), and have previously shown a significant association with successful psilocybinfacilitated smoking cessation outcomes at 6-month followup (11…”
Self-citationPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“psilocybin-facilitated treatment of alcohol dependence (24), the present findings indicate that 5-HT2AR agonists may hold therapeutic potential in treating a variety of”
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932
Self-citationPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 4×
“Consistent with previously published data (4), no participants reported an increase in bothersome visual”
InfluentialSelf-citationGriffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Self-citationMacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111420188 · Cited by 895
Self-citationValidation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin
Barrett, F. S., Johnson, M. W., & Griffiths, R. R. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609019 · Cited by 637
Self-citationLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Psilocybin-Occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu, A., Griffiths, R., & Johnson, M. (2015) · Current Drug Abuse Reviews · doi:10.2174/1874473708666150107121331 · Cited by 476
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco
Cited by
Sorted by citations
Items 501–600 of 694
A review of the complex intersection between religion, spirituality, and harm reduction
Denend, J. V., Weleff, J., Park, K., Mayorga, O., & Garcia‐Vassallo, G. (2025) · American Journal on Addictions · doi:10.1111/ajad.70046 · Cited by 1
Glenn, D. L., Choi, S. H., & Zimmerman, R. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251353251 · Cited by 1
Jevtić, M. (2025) · Engrami · doi:10.5937/engrami47-57385 · Cited by 1
Lam, K., Griffin, C., Kantipudi, S. J., Mwai, D. N., Kahn, J. G., & Marseille, E. A. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00432 · Cited by 1
Cavarra, M., Hutten, N. R. P. W., Schepers, J., Mason, N. L., Theunissen, E. L., Liechti, M. E., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2025) · British Journal of Pain · doi:10.1177/20494637251371626 · Cited by 1
Villiger, D. (2025) · Philosophy Compass · doi:10.1111/phc3.70059 · Cited by 1
Exploring the effects of microdosing on health behaviour change
Prochazkova, L., de Carvalho, L. L., Marrouch, N., Encantado, J., & Teixeira, P. J. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110688 · Cited by 3
Psilocybin alleviates high-glucose and high-lipid-induced skin aging in BJ5Ta fibroblasts
Norouzkhani, F., Gojani, E. G., Wang, B., Li, D., Shujat, S., Shrestha, A., Rodriguez‐Juarez, R., Kovalchuk, O., & Kovalchuk, I. (2025) · Biochemistry and Cell Biology · doi:10.1139/bcb-2025-0250 · Cited by 2
Baumann, M. H., Glatfelter, G. C., Walton, S. E., Krotulski, A. J., Witowski, C. G., & von Salm, J. L. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06879-8 · Cited by 1
Dleštíková, T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.105067 · Cited by 1
Perkins, D., Halman, A., Urokohara, A., Palumbo, J., Low, M., Ruffell, S., Coelho, N. L. G., Collins, L., Norman, A. F., & Sarris, J. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25767-x · Cited by 1
de Carvalho, L. L., Encantado, J., van Elk, M., Moller, A. C., Cornelius, T. M., Timmermann, C., Veiga, D., & Teixeira, P. J. (2025) · Scientific Reports · doi:10.1038/s41598-025-25818-3 · Cited by 1
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
Wopfner, A., & Soravia, L. M. (2025) · SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice · doi:10.1024/0939-5911/a000956 · Cited by 1
Exploring Access to Psychedelics Among Canadian Veterans: Pathways, Barriers, and Perceptions
Contreras, L. E., Elliott, G., Kment, F., Scott, M. A., Fascinato, D., & Mayo, L. M. (2025) · Psychedelic Medicine · doi:10.1177/28314425251387678 · Cited by 1
Associations of Couples’ Psychedelic Use with Shared Reality and Relational Well-Being
Cornelius, T. M., & Barba, T. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2607729 · Cited by 1
Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial
Weintraub, M. J., Jeffrey, J. K., Ichinose, M. C., Bergman, R. L., Shapiro, B., Barnett, G., Artin, H., Lynn, M., Salimian, A., Grody, S., et al. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121423 · Cited by 1
Koning, E., Gamberg, S., & Keshen, A. R. (2026) · Behavioral Sciences · doi:10.3390/bs16030376 · Cited by 1
Effinger, D. P., Hoffman, J. L., Quadir, S. G., Rollison, C. S., Toedt, D., Sanchez, M. E., High, M. W., Hodge, C. W., & Herman, M. A. (2026) · Nature Communications · doi:10.1038/s41467-026-71481-1 · Cited by 1
Therapist-rated predictors of response to psychedelic-assisted therapy
Viljoen, G., Bendau, A., Walter, H., Mertens, L. J., Evens, R., Wolff, M., Herwig, U., Johnson, M. W., Seynaeve, M., Koslowski, M., et al. (2026) · Nature Mental Health · doi:10.1038/s44220-026-00642-4 · Cited by 1
Self-citationMulti-metric evaluations of acute psychedelic effects on fMRI brain entropy
McCulloch, D. E.-W., Olsen, A. S., Ozenne, B., Larsen, K. O., Stenbæk, D. S., Armand, S., Madsen, M. K., Knudsen, G. M., & Fisher, P. M. (2026) · Nature Communications · doi:10.1038/s41467-026-74215-5 · Cited by 29
Psychedelics and longevity: implications for lifespan, healthspan and functional aging
Haden, M., Woods, B., Woods, T., & Tupper, K. W. (2026) · Longevity · doi:10.1080/30653495.2026.2696224 · Cited by 1
Strika-Bruneau, L., Elhssaini, C., Fauvel, B., Kervadec, E., Bezo, A., Amirouche, A., Benyamina, A., & Roméo, B. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473436 · Cited by 1
Tadeja, A. (2020) · Farmacja Polska · doi:10.32383/farmpol/127922 · Cited by 1
The rebirth of psychedelic psychiatry
Holoyda, B. J. (2021) · Current Psychiatry · doi:10.12788/cp.0079 · Cited by 1
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
Lewis, B. R., & Byrne, K. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2021.00180 · Cited by 1
Neuropharmacological analysis of the anti-addictive and therapeutic effects of psilocybin
Principe, A. (2022) · SURG Journal · doi:10.21083/surg.v14i1.6870 · Cited by 1
Mental Illness and Tobacco Usage
Asharani, P. V., & Subramaniam, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_41 · Cited by 1
Chapter 13. Theories of Interpersonal Therapy
Lipsitz‐Odess, I., Lipsitz, J. D., & Markowitz, J. C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg13 · Cited by 1
Chapter 6. Applications of Psychodynamic Psychotherapy to Specific Disorders
Leichsenring, F., & Steinert, C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg06 · Cited by 1
Chapter 26. How Our Mind Becomes Racialized
Stoute, B. J. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg26 · Cited by 1
Alam, Z., & Soma, B. (2023) · The Meducator · doi:10.35493/medu.43.18 · Cited by 1
Atualizações dos estudos com psilocibina nos transtornos psiquiátricos
Nieto, J. P. D. S. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n3-151 · Cited by 1
Treatments for Substance Use Disorders
da Costa, S. C., Moustafa, Y., Vasquez, A., & Rummans, T. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00047-6 · Cited by 1
Psychedelic Healing: A Historical, Empirical, and Personal Account
Swoap, R. (2023) · American Journal of Health Promotion · doi:10.1177/08901171231210806e · Cited by 1
Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders
Correa, R. M. S. (2024) · Annals of Bioethics & Clinical Applications · doi:10.23880/abca-16000266 · Cited by 1
Sekula, A. D., Puspanathan, P., Downey, L. A., & Liknaitzky, P. (2024) · Psychoactives · doi:10.3390/psychoactives3020010 · Cited by 2
Buzzi, B., AlSharari, S. D., Walentiny, D. M., & Damaj, M. I. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115019 · Cited by 1
Mendes, L. F. D. S., Leal, A. K. M. P., Bilibio, M. R. B., Brito, S. R. S., Noronha, M. Y. D. C., Moura, P. R. D. S. E. S., Araújo, S. J. F., & Dias, J. O. R. (2024) · Research Society and Development · doi:10.33448/rsd-v13i5.44891 · Cited by 1
Therapeutic Implications of Psilocybin in the Wake of Decriminalization
Lash, N., Tadros, G., & Tadros, E. (2024) · Integrative and Complementary Therapies · doi:10.1089/ict.2024.27206.nl · Cited by 1
Introduction: philosophy and psychedelic psychiatry
Letheby, C., & Gerrans, P. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0001 · Cited by 1
Health-related behavioral changes following the use of psychedelics in naturalistic settings
Teixeira, P. J., Jain, R., Penn, A., Cole, S. P., Jain, S., Moller, A. C., Amaro, H. D., & Raison, C. L. (2025) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2025.103161 · Cited by 1
Barnett, B. S., Anand, A., Weleff, J., King, F., & Dewey, E. N. (2025) · Psychedelic Medicine · doi:10.1177/28314425251367321 · Cited by 1
Kähönen, J. (2020) · Työväentutkimus Vuosikirja · Cited by 1
Vogel, M., Strasser, H., Thorens, G., ZULLINO, D. F., Humair, J., Simon, O., Broers, B., Haettel, C., Dévaud, C., Gothuey, I., et al. (2020) · JMIG · doi:10.53738/revmed.2020.16.676-77.0008 · Cited by 1
Kang, M., Mackay, L., Christie, D., Callon, C., & Argento, E. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00190 · Cited by 1
Psilocybin and Magic Mushrooms: Patterns of Abuse and Consequences of Recreational Misuse
Brito-da-Costa, A. M., da Silva, D. D., Madureira-Carvalho, Á., & Dinis‐Oliveira, R. J. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_130 · Cited by 1
Chapter 8. Techniques of Cognitive-Behavioral Therapy
Wright, J. H., Reis, J., & Casey, D. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg08 · Cited by 3
Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)Preprint
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · doi:10.31234/osf.io/8vks6 · Cited by 1
Self-citationTherapeutic dissociation: From non-ordinary states to psychological transformationPreprint
Clingo, J. (2024) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/ypr7w · Cited by 1
Ozols, A. B., Wei, J., Campbell, J. M., Hu, C., Qiu, S., & Gallitano, A. L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.21.595211 · Cited by 1
Lane, C. P., Tarka, V., Valentin, O., Lehmann, A., Hamel, É., & de Villers‐Sidani, E. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.27.614985 · Cited by 1
Semple, M. G., Mennenga, S. E., Smith, R. C., Dwaraka, V. B., Cahn, B. R., Tafur, J., Rabin, D. M., Yazar‐Klosinski, B., & Lewis, C. R. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.03.663007 · Cited by 1
Kolbman, N., Huels, E. R., Nelson, A. G., Summerfield, R., Byraju, K., Groenhout, T., Liu, T., Hudetz, A. G., Vanini, G., & Pal, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.12.681880 · Cited by 1
Psilocybin Experiential Therapist Training: Insights from a World-First StudyPreprint
Ioakimidis-MacDougall, G., Gardner, J., & Liknaitzky, P. (2025) · medRxiv · doi:10.1101/2025.11.15.25340324 · Cited by 1
Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen
Majić, T., Gutwinski, S., Müller, C. A., Schoofs, N., & Heinz, A. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00006-0
The role of the pharmaceutical industry in the treatment of mental health disorders.
Kleykamp, B. A., & Henningfield, J. E. (2019) · American Psychological Association eBooks · doi:10.1037/0000133-031
The Nature of Healing in the Psychedelic Experience
Criddle, A. (2020) · PhilPapers (PhilPapers Foundation)
Club Drugs and Novel Psychoactive Substances
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106
A Brief History of NPS Production and Distribution
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.003
Stimulant Drugs: Synthetic Cathinones
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.011
Stimulant Drugs: Methamphetamine
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.009
Classification Framework for Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.004
Stimulant Drugs: Amphetamine-Type Stimulants
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.008
Depressant Drugs: Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.013
The Clinical Challenge of Club Drugs and NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.005
Depressant Drugs: Benzodiazepine NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.015
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.007
Synthetic Cannabinoid Receptor Agonists (SCRAs)
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.017
Stimulant Drugs: MDMA and Drugs with Similar Effects
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.010
What Are Club Drugs and NPS and Why Are They Important?
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.002
Meil, W. M., Farrell, W., & Satti, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98514
Elaboração de escala avaliativa do setting no uso de ayahuasca
Pontual, A. A. D. D. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2021.tde-06082021-152437
ルポ 昼休みを生かしてリフレッシュ--東京急行電鉄(株)車両部長津田検車区 (作業の合間でリフレッシュ--休憩時間の過ごし方のヒント )
労働衛生編集部 (1995) · 労働衛生
Psychedelics hold promise for primary care research
Sanford, J. B. (2022) · Family Practice · doi:10.1093/fampra/cmac009
ZULLINO, D. F., Daeppen, J., Seragnoli, F., Favrod-Coune, T., Thorens, G., Simon, O., & Kuntz, A. (2021) · JMIG · doi:10.53738/revmed.2021.17.720-21.0010
Depressant Drugs: Fentanyl, Fentanyl Analogues and Other Opioid NPS
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.014
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.019
Depressant Drugs: Introduction
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.012
Depressant Drugs: Ketamine and Its Analogues
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.016
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.001
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.018
Let’s Take a Trip into Mental Health
Castello, A. (2022) · Berkeley Scientific Journal · doi:10.5070/bs326157110
Aharon-Almagor, A., & Barrett, F. S. (2022) · Research Square · doi:10.21203/rs.3.rs-1529935/v1
Mental Illness and Tobacco Usage
Asharani, P. V., & Subramaniam, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_41-1
The good, the bad, and the intoxicated
Mason, N. L. (2021) · Research Publications (Maastricht University) · doi:10.26481/dis.20210608nm
Bowden‐Jones, O., & Abdulrahim, D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623106.020
Bonson, K. R. (2020) · Wiley eBooks · doi:10.1002/9780470015902.a0029200
Forstmann, M., & Sagioglou, C. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2489x
Magic Mushrooms and Their Medicinal Use
Blum, L. (2022) · Ellipsis A Journal of Art Ideas and Literature · doi:10.46428/ejail.47.21
PSILOCIBINO EFEKTYVUMAS PSICHIKOS SUTRIKIMŲ GYDYMUI
Raudonytė, D. (2022) · Health Sciences · doi:10.35988/sm-hs.2022.150
Yaden, D. B., & Newberg, A. B. (2022) · Oxford University Press eBooks · doi:10.1093/oso/9780190665678.003.0007
P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications
da Silva, D. D., Brito-da-Costa, A. M., Martins, S., Dinis‐Oliveira, R. J., & Madureira-Carvalho, Á. (2022) · Toxicology Letters · doi:10.1016/j.toxlet.2022.07.283
Relation between Psychedelic and Transcendental Experiences
Travis, F. T. (2022) · International Journal of Psychological Studies · doi:10.5539/ijps.v14n4p31
Meyers, C. (2022) · Springer eBooks · doi:10.1007/978-3-031-17005-8_2
РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ
Matrenitsky, V. L. (2022) · Likarska sprava · doi:10.31640/2706-8803-2022-(3-4)-04 · Cited by 1
The psychedelic renaissance: can psilocybin possibly combat depression?
Raheel, H., Naeem, U., Shaikh, A., & Shaikh, O. A. (2022) · International Journal of Surgery Global Health · doi:10.1097/gh9.0000000000000089
Chapter 14. Techniques of Individual Interpersonal Psychotherapy
Swartz, H. A. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg14 · Cited by 1
Chapter 17. Techniques of Individual Supportive Psychotherapy
Rosenthal, R. N., Urmanche, A. A., & Muran, J. C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg17
Chapter 36. Supervision and Consultation in Psychotherapy
Crisp-Han, H., & Gabbard, G. O. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg36
Chapter 15. Efficacy, Indications, and Applications of Individual Interpersonal Psychotherapy
Markowitz, J. C. (2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375233.gg15
Metadata
- Authors
- Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R.
- Affiliations
- Johns Hopkins University (US)
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Corresponding author
- Johnson, Matthew W.
- Venue
- The American Journal of Drug and Alcohol Abuse
- Publisher
- Informa UK Limited
- Published
- 2016-07-21
- Volume
- 43
- Issue
- 1
- Pages
- 55-60
- ISSN
- 0095-2990 (ISSN-L)
- 1097-9891
- PMC
- PMC5641975
- OpenAlex
- W2506717582
- Cited by
- 696
- References
- 23
- Citations by year
- 2026: 53 · 2025: 100 · 2024: 89 · 2023: 112 · 2022: 131 · 2021: 63 · 2020: 83 · 2019: 17 · 2018: 31 · 2017: 13 · 2016: 3
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-01-20)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The American Journal of Drug and Alcohol Abuse (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA003889)
- Beckley Foundation (N/A)
- Heffter Research Institute (N/A)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psilocybin, smoking cessation, smoking abstinence, long-term follow-up, cognitive behavioral therapy, classic psychedelics, addiction treatment, spiritual experience
- MeSH terms
- Combined Modality Therapy, Female, Follow-Up Studies, Hallucinogens, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Cognitive Behavioral Therapy, Smoking Cessation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
